Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03707717 · ClinicalTrials.gov registry record · Phase 1
A Study to Compare the Blood Level of Bimekizumab Injected Subcutaneously Either by a Prefilled Syringe or by an Auto-injector in Adult Healthy Volunteer Participants
A Phase 1 study, sponsored by UCB Biopharma S.P.R.L..
- Completed
- Registry status
- Phase 1
- Development phase
- 189
- Enrollment target
NCT03707717: Completed Phase 1 study, sponsored by UCB Biopharma S.P.R.L..
NCT03707717 is a Phase 1 study that has completed, run by UCB Biopharma S.P.R.L.. The registered enrollment target is 189 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (215% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03707717, a Phase 1 study, has completed, sponsored by UCB Biopharma S.P.R.L..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 189 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the pharmakokinetics (PK), safety, tolerability, and immunogenicity of bimekizumab (BKZ) when administered subcutaneously (sc) via 3 different BKZ delivery devices in healthy participants.
Primary Outcome
The Cmax is the maximum plasma drug concentration of BKZ observed from pharmacokinetic samples taken at predefined time points.
Interventions
- DRUG Bimekizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 189 participants |
| Start Date | 2018-10-15 |
| Est. Completion | 2019-06-05 |
| Phase | Phase 1 |
What the finished NCT03707717 record still lists
NCT03707717 is an interventional study that assigns participants to a tested intervention. The registered 189 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (215% higher).
The record links to 0 conditions, and to 1 intervention - of which Bimekizumab is the first listed.
NCT03707717 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03707717 about?
NCT03707717 is a clinical study titled "A Study to Compare the Blood Level of Bimekizumab Injected Subcutaneously Either by a Prefilled Syringe or by an Auto-injector in Adult Healthy Volunteer Participants". The purpose of the study is to evaluate the pharmakokinetics (PK), safety, tolerability, and immunogenicity of bimekizumab (BKZ) when administered subcutaneously (sc) via 3 different BKZ delivery devices in healthy participants.
What is the current status of trial NCT03707717?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 189 participants. The study started on 2018-10-15. Estimated completion is 2019-06-05.
What interventions are being tested in trial NCT03707717?
The interventions under investigation include: Bimekizumab (DRUG).
Who is sponsoring clinical trial NCT03707717?
This trial is sponsored by UCB Biopharma S.P.R.L., which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03707717's enrollment target sits among peer trials
189 288th of 2000 higher than 1,712 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02734537 · 189 participants · Phase 2
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
- NCT05058651 · 189 participants · Phase 2
Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
- NCT05673408 · 189 participants
NIBP Validation Study
- NCT05994209 · 189 participants · Phase 1
Testing the Feasibility and Acceptability of Social Media and Digital Therapeutics to Decrease Vaping Behaviors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI